A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 82,900 shares of DCTH stock, worth $916,874. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82,900
Holding current value
$916,874
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$4.47 - $8.37 $370,563 - $693,872
82,900 New
82,900 $693,000
Q2 2023

Aug 11, 2023

BUY
$5.38 - $7.96 $50,572 - $74,824
9,400 Added 77.69%
21,500 $125,000
Q1 2023

May 12, 2023

BUY
$3.46 - $6.0 $41,866 - $72,600
12,100 New
12,100 $70,000
Q2 2021

Aug 13, 2021

SELL
$9.54 - $15.1 $151,686 - $240,090
-15,900 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$12.42 - $23.81 $1.06 Million - $2.03 Million
-85,376 Reduced 84.3%
15,900 $197,000
Q4 2020

Feb 10, 2021

BUY
$10.55 - $18.69 $1.07 Million - $1.89 Million
101,276 New
101,276 $1.82 Million

Others Institutions Holding DCTH

About DELCATH SYSTEMS, INC.


  • Ticker DCTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 8,597,680
  • Market Cap $95.1M
  • Description
  • Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...
More about DCTH
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.